By Jenna Carlesso, CT Mirror In November, two months before Connecticut’s General Assembly convened for the 2021 regular session, lawmakers stood under the portico at the front of the state Capitol and pledged to tackle the cost of health care and access to medical services, mainly through a public option bill. Three months later, on the same day he released his biennial budget proposal, Gov. Ned Lamont unveiled his own legislation aimed at addressing health care reform that included an annual cap on prescription drug costs. But momentum surrounding both ambitious bills has slowed with only a month left in the session and opposition mounting. Legislative leaders now say Lamont’s prescription drug cap, though well-intentioned, would be a tough sell in a year when Pfizer and other drug companies are producing life-saving COVID-19 vaccines. And an infusion of federal money that has helped fund additional subsidies on Connecticut’s insurance exchange has undercut a key aspect of the public option bill.